Órtese com impressão 3D para ombro: relato de caso / 3D print orthesis for shoulder: case report

Subluxação do ombro é a complicação musculoesquelética mais comum das afecções do Sistema Nervoso Central e Periférico, que leva a diminuição do movimento, da função e aumento de dor. Órtese é um dos recursos auxiliares utilizados no tratamento desta patologia e visa corrigir deformidade, diminuir dor e proporcionar função ao membro acometido. Objetivo: Este trabalho propõe uma nova metodologia para projetar e fabricar órteses customizadas estabilizadoras de ombro utilizando as tecnologias de aquisição 3D por escaneamento e de fabricação por Impressão 3D, e assegurar melhor adaptabilidade e maior conforto para o usuário. Método: A metodologia utilizada neste estudo foi dividida em cinco fases: estudo de caso, escaneamento, modelagem e impressão em 3D; e acabamento. O estudo de caso do usuário com lesão de plexo braquial motivou o projeto de desenho original de órtese híbrida, personalizada e manufaturada em 3D, usando estrutura rígida e faixas de tração, com objetivo de estabilizar o ombro, diminuir a dor e permitir função. Resultados: Após escaneamento em 3D utilizou-se softwares especializados para processar a imagem tridimensional STL. Realizaram-se otimizações do projeto com geração de modelos e peças prototipadas em FDM; avaliada pelo usuário. O conceito desenvolvido foi: órtese personalizada, fácil de higienizar e vestir, resistente, articulada, veste nos dois braços com faixas de tração em tecido rígido acoplado à cintura. Conclusão: O teste com usuário corroborou com o conceito projetado e mostrou um protótipo preliminar com bom acoplamento ao tronco, tração satisfatória e possibilidade de realizar um maior número de AVD´s com menos dor e/ou sensação de cansaço

Subluxation of the shoulder is the most common musculoskeletal complication of Central and Peripheral Nervous System disorders, which leads to decreased movement, function, and increased pain. Objective: Orthosis is one of the assistive devices used in the treatment of this pathology and it focuses in correcting deformity, decreasing pain and providing function to the affected member. This study proposes a new methodology for designing and manufacturing customized shoulder stabilization orthoses with 3D scan image acquisition and 3D printing technologies, for ensuring better adaptability and comfort for the user. Method: The methodology used in this study was divided into five phases: case study, scanning, modeling and 3D printing; and finishing. The case study included a user with brachial plexus injury that motivated the original design of hybrid orthosis, personalized and manufactured in 3D, with rigid structure and traction straps, for stabilizing the shoulder, reduce pain and allowing function. Results: After 3D scanning, we used specialized software to process the three-dimensional STL image. Optimization of the project with generation of models and prototyped parts in FDM based on the user evaluations was performed. The developed concept was: personalized orthosis, easy to clean and wear, resistant, articulated, for wearing in both arms with traction straps in rigid fabric coupled to the waist. Conclusion: The user test corroborated with the designed concept and showed a preliminary prototype with good trunk coupling, satisfactory traction and possibility of performing a greater number of ADLs with less pain and/or tiredness

Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study

Abstract: Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free wáter excretion, but its efficacy and safety in cirrhotic patients remain unclear. Material and methods. We studied the usage and safety of tolvaptan in cirrhotic patients in a real-life, non-randomized, multicenter prospective cohort study. Forty-nine cirrhotic patients with hyponatremia were treated with tolvaptan 15 mg daily, and 48 patients not treated with tolvaptan in the same period served as controls. Improvement in serum sodium level was defined as an increase in serum sodium from < 125 to ≥ 125 mmol/L or from 125-134 to ≥ 135 mmol/L on day 7. Results. Twenty-three (47%) patients in the tolvaptan group and 17 (35%) in the control group had normal serum sodium on day 7 (p = 0.25). Serum sodium improved in 30 (61%) patients in the tolvaptan group and 17 (35%) patients in the control group (p = 0.011). Adverse events occurred in 46-47% of patients in both groups, and tolvaptan was not associated with worsened liver function. No patient with normal serum sodium on day 7 died within 30 days of treatment, whereas 16% of those with persistent hyponatremia died (p = 0.0019). Conclusion. In conclusion, short-term tolvaptan treatment is safe and can improve serum sodium level in cirrhotic patients with hyponatremia. Normalization of serum sodium level is associated with better survival.